Compare Citius Pharmaceuticals Inc (CTXR) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while BlackRock TCP Capital Corp trades at $3.92 (market cap $327.64M). The key difference: BlackRock TCP Capital Corp is far larger — about 16.4× Citius Pharmaceuticals Inc's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TCPC | |
|---|---|---|
Market Cap | $20.01M | $327.64M |
Sector | Health | Financials |
52-Week High | $1.82 | $7.26 |
52-Week Low | $0.48 | $3.13 |
Enterprise Value | $16.23M | — |
Dividend Yield | — | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
TCPC trades at $3.88, down 1.52% today, with a bullish technical trend and neutral oscillators. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company announced a $523 million portfolio sale to reduce leverage. The stock shows a high P/S ratio of 70.7 but trades below book value with a P/B of 0.59. Dividends of $0.17 per share are scheduled for H1 and H2 2026.
Outlook is mixed: strategic moves and dividend yield near 8.8% offer value, but negative revenue, net losses, and a class action lawsuit pose risks. Analyst consensus leans hold, with 30.8% buy ratings. Further upside depends on successful execution of the strategic review and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
